Rethinking flow: the paradox of renoprotection without increased renal blood flow in cardiopulmonary bypass Authors: Shiksha Mohan, Ronald A. Shaju, Sharan Misra, Titiksha Sharma, Veeraj K. Sirivolu, Abhinav Rajkumar, Anthony Rodas-Camacho, Aizah Zaidi, Dhruv Dhingra, Ilma Khan, Rishav Bhattacharya, Vishal Pancholy, Shivam Banerjee, Shreyo Ghosh, Shiyi Li, Kenneth K. Liao, Carl P. Walther, Nandan K. Mondal Published: 2026 Mitigating acute kidney injury (AKI) following cardiac surgery requiring cardiopulmonary bypass (CPB) remains a central challenge in perioperative medicine. CPB-associated AKI, with an incidence of 15–30% and significant implications for mortality and morbidity, is a multifactorial insult where renal hypoxia is postulated to play a critical role (1,2). Clinical studies have increasingly suggested that systemic oxygen delivery during CPB may be a key determinant of postoperative renal injury. In the Goal-Directed Perfusion Trial (GIFT), Ranucci and colleagues demonstrated that maintaining indexed oxygen delivery (DO2I) ≥280 mL·min−1·m−2 during CPB reduced the incidence of stage 1 postoperative AKI compared with conventional perfusion strategies (3). In this context, the randomized controlled trial by Wijk and colleagues, published in Anesthesiology in 2025, provides a compelling and somewhat paradoxical contribution to the literature (4). Their study explores a seemingly simple intervention: increasing CPB pump flow by 20%. It leads to intricate conclusions that challenge basic hemodynamic explanations and urge us to enhance our understanding of renal physiology during artificial perfusion. The central, and most intriguing, finding of this trial is that a higher CPB flow (2.9 L·min−1·m−2) increased glomerular filtration rate (GFR) and attenuated tubular injury without concurrently increasing total renal blood flow (RBF) or altering the global renal oxygen demand-supply relationship. This dissociation between macroscopic renal perfusion and functional outcomes forces a deeper look beyond conventional metrics and into the complex microcirculatory and regional dynamics of the kidney. The apparent effects of standard versus high CPB pump flow on renal perfusion and oxygenation, as inferred from the trial by Wijk and colleagues, are shown in Figure 1. The study at a glance: rigor and revelations. Mechanism of renoprotection with high CPB flow via intrarenal flow redistribution. CPB, cardiopulmonary bypass; NAG, N-acetyl-β-D-glucosaminidase. Wijk et al. conducted a prospective, randomized, non-blinded trial in 36 adult cardiac surgery patients, comparing a standard flow (SF) (2.4 L·min−1·m−2) with a high flow (HF) (2.9 L·min−1·m−2) strategy throughout CPB. The study rigorously measured challenging renal physiologic metrics. The use of a renal vein catheter, combined with infusion clearance techniques for para-aminohippuric acid (PAH) and iohexol, represents the gold standard for direct measurement of RBF and GFR, respectively (4). As anticipated, the HF strategy robustly increased systemic DO2I. However, the primary outcome, RBF, was notably unchanged between groups. This suggests the renal vasculature, governed by its potent autoregulatory mechanisms, did not passively dilate. The comparative outcomes are summarized in Table 1. Table 1Key renal and systemic outcomesParameterSF groupHF groupInterpretationSystemic oxygen deliveryIncrease (smaller)Increase (large)Flow intervention produced the intended systemic effect (higher systemic oxygen delivery), while renal oxygenation indices did not differRBFNo significant changeNo significant changePrimary outcome unchangedGFRNo significant changeSignificant increase (~10%)Suggests increased functionTubular injury (peak NAG)Higher62% lowerSuggests renoprotectionNorepinephrine requirementHigher dose~50% lower doseHF achieved pressure with less vasoconstrictionGFR, glomerular filtration rate; HF, high flow; NAG, N-acetyl-β-D-glucosaminidase; RBF, renal blood flow; SF, standard flow. Key renal and systemic outcomes GFR, glomerular filtration rate; HF, high flow; NAG, N-acetyl-β-D-glucosaminidase; RBF, renal blood flow; SF, standard flow. The key differential outcomes emerged in functional and injury markers: ❖ Increased glomerular filtration: GFR increased by ~10% in the HF group during CPB. This was accompanied by a commensurate increase in renal sodium filtration and reabsorption. ❖ Increased glomerular filtration: GFR increased by ~10% in the HF group during CPB. This was accompanied by a commensurate increase in renal sodium filtration and reabsorption. ❖ Attenuated tubular injury: the peak urinary excretion of the tubular injury biomarker N-acetyl-β-D-glucosaminidase (NAG) was 62% lower in the HF group after CPB. This may be a clinically significant finding, as NAG has been shown to be a sensitive early marker of proximal tubular damage and a predictor of subsequent AKI (5). ❖ Attenuated tubular injury: the peak urinary excretion of the tubular injury biomarker N-acetyl-β-D-glucosaminidase (NAG) was 62% lower in the HF group after CPB. This may be a clinically significant finding, as NAG has been shown to be a sensitive early marker of proximal tubular damage and a predictor of subsequent AKI (5). Resolving the paradox: a shift from perfusion quantity to oxygen delivery quality How can we reconcile improved GFR and reduced tubular injury without increased total RBF? The authors propose a compelling hypothesis: a redistribution of intra-RBF from the cortex to the medulla. This theory is supported by the significant decrease in PAH extraction in the HF group. A fall in its extraction fraction suggests a greater proportion of renal plasma flow is passing through nephrons with lower extraction efficiency, namely, the juxtamedullary nephrons whose long loops of Henle dive into the oxygen-starved medulla (6,7). This proposed intrarenal flow redistribution has two critical consequences: ❖ Uncoupling of GFR from oxygen consumption: an increase in GFR typically mandates a proportional increase in renal oxygen consumption (RVO2), as energy-dependent sodium reabsorption in the thick ascending limb is the kidney’s primary consumer of oxygen (8). In this study, despite increased GFR and sodium reabsorption in the HF group, RVO2 remained stable. This “uncoupling” can be explained if the increased filtration and reabsorption occurred in juxtamedullary nephrons, which experimental data suggest have lower oxygen consumption per unit of sodium reabsorbed than cortical nephrons (9). ❖ Uncoupling of GFR from oxygen consumption: an increase in GFR typically mandates a proportional increase in renal oxygen consumption (RVO2), as energy-dependent sodium reabsorption in the thick ascending limb is the kidney’s primary consumer of oxygen (8). In this study, despite increased GFR and sodium reabsorption in the HF group, RVO2 remained stable. This “uncoupling” can be explained if the increased filtration and reabsorption occurred in juxtamedullary nephrons, which experimental data suggest have lower oxygen consumption per unit of sodium reabsorbed than cortical nephrons (9). ❖ Enhanced medullary oxygenation: the renal medulla exists on the brink of hypoxias (10). If higher CPB flow preferentially augments medullary perfusion, it would alleviate regional hypoxia in the most vulnerable segment of the nephron, directly protecting the tubular cells. Such a regional improvement is “invisible” to a renal vein catheter, as renal venous oxygen saturation is dominated by the well-oxygenated, high-flow cortical effluent. This aligns with experimental CPB models demonstrating that increased pump flow improves medullary oxygenation without necessarily altering cortical perfusion or total RBF (11). ❖ Enhanced medullary oxygenation: the renal medulla exists on the brink of hypoxias (10). If higher CPB flow preferentially augments medullary perfusion, it would alleviate regional hypoxia in the most vulnerable segment of the nephron, directly protecting the tubular cells. Such a regional improvement is “invisible” to a renal vein catheter, as renal venous oxygen saturation is dominated by the well-oxygenated, high-flow cortical effluent. This aligns with experimental CPB models demonstrating that increased pump flow improves medullary oxygenation without necessarily altering cortical perfusion or total RBF (11). This underscores a pivotal conceptual shift, illuminated by this study, that the focus for renal protection must shift from perfusion quantity (total RBF) to oxygen delivery quality (regional oxygenation and efficiency of use). The norepinephrine factor and clinical implementation An additional, synergistic factor is the significantly lower vasopressor requirement in the HF group. As reported by Wijk and colleagues, the SF group required approximately twice the norepinephrine dose to maintain the target mean arterial pressure (MAP) (4). Experimental data indicate norepinephrine can reduce medullary perfusion and oxygenation (12). Therefore, the HF strategy, achieving pressure via flow rather than vasoconstriction, likely avoids an additional renal insult. This challenges the common clinical heuristic of prioritizing MAP targets pharmacologically, suggesting that ‘flow as pressure’ may be superior to ‘pressure via vasoconstrictors’ for renal protection. From a practical standpoint, the 20% increase in flow is a simple, low-cost, and immediately feasible intervention. However, safe application requires forethought: cannula and oxygenator sizing must be adequate to handle higher flows without excessive shear stress or hemolysis (13). Importantly, cannulas are typically selected prior to CPB based on the anticipated cardiac index. Therefore, adopting a higher flow rate may necessitate larger cannulation approaches, which carry their own procedural and vascular risks (14). Vigilance against hemodilution is also necessary. Increasing circuit flow raises theoretical concerns about shear-related blood cell injury and increased embolic load, especially to the brain (15). While these risks may be minor in experienced centers, it is important to note that augmenting flow is not a trivial adjustment but requires planning and technical consideration. This strategy may be particularly relevant for high-risk patients, such as those undergoing heart transplantation or with pre-existing renal impairment. Limitations and unanswered questions No study is without limitations, and the authors acknowledge theirs transparently. The baseline imbalance in preoperative renal function, with the HF group having a lower estimated GFR (eGFR), is a notable limitation. However, the fact that the HF group still demonstrated a significant improvement in eGFR during CPB arguably strengthens the main finding, as one might expect a sicker kidney to be less responsive. The relatively small sample size, powered for the primary outcome of RBF, means that other comparisons, particularly the NAG results, should be interpreted as hypothesis-generating, though the effect size is impressive. The non-blinded design introduces potential for bias, though the objective nature of the primary laboratory-based outcomes mitigates this concern to some extent. An additional consideration is the study’s relatively strict exclusion criteria. Patients with a body mass index (BMI) of >32 kg/m2, planned deep hypothermia, or severe pre-existing renal dysfunction (eGFR <30 mL·min−1·1.73 m−2) were excluded. Critically, individuals with advanced chronic kidney disease (CKD) represent the population at the greatest risk for postoperative AKI (16) and theoretically may derive the greatest benefit from the augmented flow rate. Therefore, the generalizability of these findings to the high-risk cohort remains uncertain. Crucially, the study was not designed or powered to detect differences in hard clinical outcomes, such as the incidence of stage 2 or 3 AKI according to “Kidney Disease: Improving Global Outcomes” (KDIGO) criteria, or the need for renal replacement therapy. The validity and physiological insights of NAG as a surrogate are established, but the critical question remains unaddressed: Does this strategy prevent clinically significant AKI? A larger, multi-center trial is necessary to find an answer. Finally, the study leaves us with a physiological puzzle: why did a longer duration of HF (in this study) not improve global renal oxygen extraction (RO2Ex), whereas a shorter period did? The authors speculate about slow-acting autoregulatory mechanisms, such as tubuloglomerular feedback, which may have normalized RO2Ex over time. This temporal aspect of renal adaptation to CPB is a fascinating area for future research. Another relevant factor is that the bypass circuit was primed with crystalloid rather than starch-based colloids, which have been associated with renal morbidity in cardiac surgery (17). This methodological choice may have reduced baseline perioperative kidney stress and should be considered when extrapolating these findings to conditions that require alternative priming solutions. Conclusions The work by Wijk and colleagues is a significant step forward. It successfully challenges a simplistic “more flow, more blood” model and directs our attention to the kidney’s intricate regional physiology. The study provides robust physiological evidence that a modest increase in CPB flow can enhance glomerular filtration and reduce biochemical evidence of tubular damage, likely by optimizing medullary oxygenation and minimizing vasopressor exposure. Viewed alongside the GIFT trial (3), these results suggest that strategies aimed at preserving systemic oxygen delivery during CPB may confer renal protection not merely through blanket, global perfusion changes but through improvements within vulnerable renal microenvironments. This research elevates the discussion from whether flow matters to how it matters: reinforcing attention on the renal medulla (often greatly overlooked clinically, yet the most hypoxia-prone compartment). It encourages a shift from global, pressure-centric management toward organ-focused perfusion strategies that aim to protect vulnerable regional physiology. The essential next step is a large, multicenter randomized controlled trial with postoperative clinical AKI as the primary endpoint. Until then, this trial serves as both a beacon and a compass, pointing toward a more nuanced understanding of flow’s profound role in making cardiac surgery safer for the kidney. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0201/prf